Akt/mTOR Counteract the Antitumor Activities of Cixutumumab, an Anti-Insulin–like Growth Factor I Receptor Monoclonal Antibody
Dong Hoon Shin(National Cancer Center), Ho‐Young Lee(Seoul National University of Science and Technology)
Cited by 43
Related Papers
Molecular targeted therapy for anticancer treatment
|Experimental & Molecular Medicine|2022|495
Heterodimerization of Insulin-like Growth Factor Receptor/Epidermal Growth Factor Receptor and Induction of Survivin Expression Counteract the Antitumor Action of Erlotinib
|Cancer Research|2006|336
Hypoxia-inducible Factor 1α and Antiangiogenic Activity of Farnesyltransferase Inhibitor SCH66336 in Human Aerodigestive Tract Cancer
|JNCI Journal of the National Cancer Institute|2005|97
Effects of Insulin-like Growth Factor Binding Protein-3 and Farnesyltransferase Inhibitor SCH66336 on Akt Expression and Apoptosis in Non-Small-Cell Lung Cancer Cells
|JNCI Journal of the National Cancer Institute|2004|74